Publication Topic

Greene N, Song M. 2011. Predicting in vivo safety characteristics using physicochemical properties and in vitro assays. Fut Med Chem 3(12):1503-1511; doi: 10.4155/fmc.11.89. PMID: 21882943.

Collins N. Preladenant: Preclinical development case study. Early Development Course: A Merck Polytechnic Institute Premier Course, Princeton, NJ, 2011.

Greene N, Aleo MD, Louise-May S, Price DA, Will Y. 2010. Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. Bioorg Med Chem Lett 20(17):5308-5312; doi: 10.1016/j.bmcl.2010.06.129. PMID: 20655216.

Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ. 2010. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol 23(7):1215-1222; doi: 10.1021/tx1000865. PMID: 20553011.

Sistare FD, Dieterle F, Troth S, Holder DJ, Gerhold D, …, Collins N, et al. 2010. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol 28(5):446–454; doi: 10.1038/nbt.1634. PMID:

Robison TW. Toxicology in the nonclinical development of drugs and biologics. Pharmaceutical Education and Research Institute, Genetic Toxicology, Arlington, VA, September 2009.

Robison TW. Toxicology in the nonclinical development of drugs and biologics. Pharmaceutical Education and Research Institute, Genetic Toxicology, Arlington, VA, September 2008.

Robison TW. Toxicology in the nonclinical development of drugs and biologics. Pharmaceutical Education and Research Institute, Genetic Toxicology, Arlington, VA, September 2007.

Burns AM, Woods CG, Rusyn I. Regulation of the mevalonate pathway influences proliferative effects of Wy-14,643 in mouse liver. Abstract 864, Society of Toxicology 46th Annual Meeting Charlotte, NC, March 2007.

Robison TW. Toxicology in the nonclinical development of drugs and biologics. Pharmaceutical Education and Research Institute, Genetic Toxicology, Arlington, VA, September 2006.

Rose WC, Marathe PH, Jang G, Monticello TM, Balasubramanian BN, Long B, Fairchild C, Wall ME, Wani MC. 2006. Novel fluoro-substituted campthothecins: In vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization. Cancer Chemother Pharmacol 58(1):73-85; doi: 10.1007/s00280-005-0128-y.

Ulrich K, Stern M, Goddard ME, Williams J, Zhu J, Dewar A, Painter HA, Jeffery PK, et al. 2005. Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury. Lung Cell Molec Physiol 288(6):L1179-92; doi: 10.1152/ajplung.00450.2004. PMID: 15681392.

Kim DJ, Murray I, Burns AM, Gonzalez FJ, Perdew GH, Peters JM. 2005. Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 280(10):9519-9527; doi: 10.1074/jbc.M413808200. PMID: 15632134.

Strobel HW, Thompson CM, Antonovic L. 2001. Cytochromes P450 in brain: Function and significance. Curr Drug Metabol 2(2):199–214; doi: 10.2174/1389200013338577. PMID: 11469726.

Tao L, Wadsworth S, Mercer J, Mueller C, Lynn K, Siekierka J, August A. 2002. Opposing roles of serine/threonine kinases MEKK1 and LOK in regulating the CD28 responsive element in T- cells. Biochem J 363(Pt 1):175–182; doi: 10.1042/0264-6021:3630175. PMID: 11903060.

Choksi NY, Nix WB, Wyrick SD, Booth RG. Phenylaminotetralins activate histamine H1 receptors to stimulate dopamine synthesis in vivo in rat brain. Poster presented at the Receptor Chemistry Towards the Third Millennium – 12th Camerino-Noordwijkerhout Symposium, 1999.

Choksi NY, Hussain A, Booth RG. 1996. 2-Phenylaminoadenosine stimulates adenylyl cyclase activity and dopamine biosynthesis through an A2 receptor mediated mechanism. Brain Res 761(1):151–155; doi: 10.1016/s0006-8993(97)00445-9. PMID: 9247078.

Youkilis E, McCartney M, Schmitt D, Woods E. 1986. Subchronic intravenous toxicity evaluation of Methionine-Enkephalin (Met-Enk). Abstract 1234, Society of Toxicology 25th Annual Meeting, New Orleans, LA, March 1986.